跳至主要内容
临床试验/NCT00234871
NCT00234871已完成4 期

A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy

Abbott0 个研究点目标入组 357 人开始时间: 2004年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Abbott
入组人数
357
主要终点
Changes in urinary albumin:creatinine ratio

研究概览

简要总结

The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hypertension
  • Albuminuria

排除标准

  • Type 1 DM.
  • Subject has severe hepatic dysfunction at Screening as determined by liver function tests:
  • Bilirubin > 2.0 mg/dL.
  • ALT and/or AST > 3 times the upper limit of normal.
  • Subject has poorly controlled diabetes, based on HbA1c > 10% at Screening.
  • Subject has non-diabetic renal disease.
  • Subject has a hypersensitivity to ACE inhibitor, CCB, torsemide or sulfonylureas.

研究组 & 干预措施

1

Active Comparator

干预措施: trandolapril/verapamil (Drug)

2

Active Comparator

干预措施: Lotrel (amlodipine/benazepril) (Drug)

结局指标

主要结局

Changes in urinary albumin:creatinine ratio

时间窗: 36 weeks

次要结局

  • Changes in blood pressure (BP), BP control, ABPM, proteinuria, GFR lipid parameters, glycemic control, quality of life, CRP, oxidative stress markers, clinical safety labs and adverse events.(36 weeks)

研究者

发起方
Abbott
申办方类型
Industry

相似试验